Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Asset Writedowns and Impairment: 2024-2025

Historic Asset Writedowns and Impairment for Ptc Therapeutics (PTCT) over the last 1 years, with Sep 2025 value amounting to $400,000.

  • Ptc Therapeutics' Asset Writedowns and Impairment fell 69.65% to $400,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $161.2 million, marking a year-over-year change of. This contributed to the annual value of $159.5 million for FY2024, which is 26.75% down from last year.
  • Per Ptc Therapeutics' latest filing, its Asset Writedowns and Impairment stood at $400,000 for Q3 2025, which was down 99.75% from $159.5 million recorded in Q4 2024.
  • In the past 5 years, Ptc Therapeutics' Asset Writedowns and Impairment registered a high of $159.5 million during Q4 2024, and its lowest value of -$32,000 during Q2 2024.
  • Over the past 2 years, Ptc Therapeutics' median Asset Writedowns and Impairment value was $859,000 (recorded in 2024), while the average stood at $40.3 million.
  • Data for Ptc Therapeutics' Asset Writedowns and Impairment shows a maximum YoY tumbled of 69.65% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Ptc Therapeutics' Asset Writedowns and Impairment stood at $159.5 million in 2024, then slumped by 69.65% to $400,000 in 2025.
  • Its last three reported values are $400,000 in Q3 2025, $159.5 million for Q4 2024, and $1.3 million during Q3 2024.